Clinical trials: B Cell
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT01306643
- Testing
- Idelalisib
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
This phase II trial studies how well giving vorinostat, cladribine, and rituximab together works in treating patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or B cell non-Hodgkin's lymphoma (NHL)…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT00764517
- Testing
- Cladribine, Laboratory Biomarker Analysis, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- OHSU Knight Cancer Institute
Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent
A Phase II Study of Doxycycline in Relapsed NHL
The purpose of this study is to determine whether doxycycline is effective in the treatment of relapsed Non Hodgkin Lymphomas (NHL).
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent, Lymphoma, Follicular, Marginal Zone B-Cell Lymphoma
- Trial name
- NCT02086591
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Pancreatic Cancer
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy.
- Trial name
- NCT03848182
- Testing
- Gemcitabine, TT vaccine booster
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma, Large-Cell, Diffuse
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
- Trial name
- NCT00622388
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effects of idelalisib with obinutuzumab versus the combination of chlorambucil and obinutuzumab on progression-free survival (PFS) in participants with previously untreated…
- Trial name
- NCT01980875
- Testing
- Idelalisib, Chlorambucil, Obinutuzumab
- Where
- 18 sites in United States, Australia and 6 more
- Volunteers
- 57 people
- Sponsor
- Gilead Sciences
Diffuse Large B-cell Lymphoma
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma
This is a multicenter, double-blind, randomized study comparing the efficacy, pharmacokinetics (PK)/pharmacodynamics (PD), safety and immunogenicity profile of RTXM83 (rituximab biosimilar) vs reference rituximab (MabThera®)…
- Trial name
- NCT02268045
- Testing
- RTXM83, Mabthera
- Where
- 87 sites in Argentina, Brazil and 10 more
- Volunteers
- 272 people
- Sponsor
- mAbxience Research S.L.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Perifosine inhibits the AKT pathway (a way cells communicate with each other). This pathway is felt to be important in the development of several types of cancers including chronic lymphocytic leukemia (CLL) or small lymphocytic…
- Trial name
- NCT00873457
- Testing
- perifosine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Daphne Friedman
Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT03583424
- Testing
- Carmustine, Cytarabine, Etoposide
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell…
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Trial name
- NCT05121103
- Testing
- EZM0414
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Epizyme, Inc.
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin and venetoclax in participants with R/R FL…
- Trial name
- NCT03135262
- Testing
- Idasanutlin, Obinutuzumab, Venetoclax
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00513474
- Testing
- busulfan, cyclophosphamide, cyclosporin-A
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the safety and effectiveness of a new drug called lenalidomide (Revlimid) for treating patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who relapsed after their…
- Trial name
- NCT00439231
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Georg Aue, M.D.
Chronic Lymphocytic Leukemia
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL.
- Trial name
- NCT02315768
- Testing
- GA101, Ibrutinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego
B-cell Lymphoma
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
This phase I clinical study was to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in Chinese participants with B-cell lymphoma by…
- Trial name
- NCT03189524
- Testing
- Zanubrutinib
- Where
- 4 sites in China
- Volunteers
- 44 people
- Sponsor
- BeiGene
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03088878
- Testing
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib
- Where
- 12 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oncternal Therapeutics, Inc
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.